Beyond the data deluge: Immune profiling in early immuno-oncology trials

Designing immune monitoring programs for early-phase immuno-oncology trials requires not only scientific rigor but also strategic decisions about cost, technology, and operational logistics.

This webinar provides practical guidance on how to select and integrate advanced assay platforms such as high-content flow cytometry and multiplex immunofluorescence (mIF), with a clear focus on cost, data relevance, and operational feasibility.

Experts from Precision for Medicine will share how to extract meaningful data instead of just generating large data sets. They will also cover key considerations for experimental design, sample collection, and platform integration to ensure impactful outcomes for pharmacodynamic and biomarker studies.

Key Takeaways

How to Prioritize Cost and Data Value: Evaluate up front which advanced immune monitoring technologies deliver useful data versus overwhelming volume especially with high-content platforms like flow and mIF.
Choosing & Integrating Platforms: Strategic approaches to selecting and combining complementary and independent assay technologies for robust immune monitoring across sample types.
Balancing Science, Operations, and Logistics: Practical guidance on experimental design and sample handling that maximizes data relevance while streamlining clinical operations.
Avoiding Common Pitfalls: Key factors to avoid typical missteps in platform selection, assay planning, and biomarker strategy for impactful and effective early-phase studies.

Register now to gain expert insights into building smarter immune monitoring strategies.

First name

Last name

Company

Job Title

Country

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.

If you are experiencing problems with your registration, please try the Zoom registration page.

Deb Phippard

Chief Scientific Officer, Precision for Medicine

Deb Phippard, PhD, is the Chief Scientific Officer at Precision for Medicine. With over 25 years of experience in biotechnology and clinical translational research, she is a veteran in the pharma industry and an expert in biomarker-driven clinical trial design and execution. Dr. Phippard leads biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. She spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.

Rachel Owen

Vice President, Immunology, Precision for Medicine

Rachel Owen, PhD is the vice president of immunology at Precision for Medicine. She is a global leader in immuno-oncology and infectious disease research, offering vast expertise in flow cytometry assay development, cell-based assays, and biomarker discovery. She is accustomed to both early and late phase clinical trials, making her a proficient strategist in translational studies. With her focus on providing valuable data for scientific discovery, she strengthens her partnerships in research.

Moderator

Jaime Green

Freelance Journalist & Science Writer

Jaime Green is a freelance science writer and author. Her work has appeared in The New York Times Magazine, The Atlantic, Aeon, Popular Science, Slate, Astrobites, and elsewhere. She is the series editor of The Best American Science and Nature Writing and author of The Possibility of Life: Science, Imagination, and Our Quest for Kinship in the Cosmos.